MicroRNA-107 prevents amyloid-β-induced neurotoxicity and memory impairment in mice

Shu,Bohui; Zhang,Xiaoyan; Du,Ganqin; Fu,Qizhi; Huang,Lina

doi:10.3892/ijmm.2017.3339

MicroRNA-107 prevents amyloid-β-induced neurotoxicity and memory impairment in mice

Authors:
- Bohui Shu
- Xiaoyan Zhang
- Ganqin Du
- Qizhi Fu
- Lina Huang
View Affiliations

Affiliations: The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
Published online on: December 22, 2017 https://doi.org/10.3892/ijmm.2017.3339
Pages: 1665-1672

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The pathogenesis of Alzheimer's disease (AD) has still not been fully elucidated, however it is thought that the build up of amyloid plaque at least partially causes the symptoms of AD. MicroRNAs (miRNAs) are endogenous non‑coding small RNA molecules that regulate the expression and degradation of proteins. The present study induced symptoms of AD in mice via intraventricular injection of amyloid‑β 1‑42 (Aβ1‑42), which decreased levels of miR‑107. However, miR‑107 levels increased following administration of miR‑107 mimic, a double‑stranded RNA molecule designed to imitate the native miRNA. Intraventricular injection of Aβ1‑42 aggregates led to spatial memory impairments, inhibited hippocampal long‑term potentiation (LTP) and resulted in the loss of pyramidal cells in the CA1 region of the hippocampus. The miR‑107 mimic reversed the impairments of spatial memory and LTP and the loss of pyramidal neurons caused by Aβ neurotoxicity. Furthermore, the miR‑107 mimic reversed the Aβ‑induced increase in Aβ1‑42 and phosphorylated Tau levels. Critically, Aβ1‑42 injection decreased levels of brain‑derived neurotrophic factor and reduced the phosphorylation of tyrosine receptor kinase B and protein kinase B; these changes were reversed following treatment with the miR‑107 mimic. Collectively, these results demonstrated that miR‑107 may be a potential target for the treatment of AD.

View Figures

View References

1	Selkoe DJ and Hardy J: The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 8:595–608. 2016. View Article : Google Scholar : PubMed/NCBI
2	Gong NJ, Chan CC, Leung LM, Wong CS, Dibb R and Liu C: Differential microstructural and morphological abnormalities in mild cognitive impairment and Alzheimer's disease: Evidence from cortical and deep gray matter. Hum Brain Map. 38:2495–2508. 2017. View Article : Google Scholar
3	Luo J, Wärmländer SK, Gräslund A and Abrahams JP: Cross-interactions between the Alzheimer disease amyloid-beta peptide and other amyloid proteins. A FURTHER ASPECT OF THE AMYLOID CASCADE HYPOTHESIS. J Biol Chem. 292:20462017. View Article : Google Scholar
4	Hong X, Liu J, Zhu G, Zhuang Y, Suo H, Wang P, Huang D, Xu J, Huang Y, Yu M, et al: Parkin overexpression ameliorates hippocampal long-term potentiation and beta-amyloid load in an Alzheimer's disease mouse model. Hum Mol Genet. 23:1056–1072. 2014. View Article : Google Scholar
5	Li F, Han G and Wu K: Tanshinone IIA alleviates the AD phenotypes in APP and PS1 transgenic mice. BioMed Res Int. 2016:76318012016.PubMed/NCBI
6	Wang P, Wu Q, Wu W, Li H, Guo Y, Yu P, Gao G, Shi Z, Zhao B and Chang YZ: Mitochondrial ferritin deletion exacerbates β-amyloid-induced neurotoxicity in mice. Oxid Med Cell Longev. 2017:10203572017. View Article : Google Scholar
7	Zhu J, Liao S, Zhou L and Wan L: Tanshinone IIA attenuates Aβ25-35 -induced spatial memory impairment via upregulating receptors for activated C kinase1 and inhibiting autophagy in hippocampus. J Pharm Pharmacol. 69:191–201. 2017. View Article : Google Scholar
8	Quinlan S, Kenny A, Medina M, Engel T and Jimenez-Mateos EM: MicroRNAs in Neurodegenerative Diseases. Int Rev Cell Mol Biol. 334:309–343. 2017. View Article : Google Scholar : PubMed/NCBI
9	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
10	Reddy KB: MicroRNA (miRNA) in cancer. Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
11	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
12	Recasens A, Perier C and Sue CM: Role of microRNAs in the regulation of α-Synuclein expression: A systematic review. Front Mol Neurosci. 9:1282016. View Article : Google Scholar
13	Molasy M, Walczak A, Szaflik J, Szaflik JP and Majsterek I: MicroRNAs in glaucoma and neurodegenerative diseases. J Hum Genet. 62:105–112. 2017. View Article : Google Scholar
14	Impey S, Davare M, Lesiak A, Fortin D, Ando H, Varlamova O, Obrietan K, Soderling TR, Goodman RH and Wayman GA: An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling. Mol Cell Neurosci. 43:146–156. 2010. View Article : Google Scholar :
15	Nagaraj S, Laskowska-Kaszub K, Dębski KJ, Wojsiat J, Dąbrowski M, Gabryelewicz T, Kuźnicki J and Wojda U: Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects. Oncotarget. 8:16122–16143. 2017. View Article : Google Scholar : PubMed/NCBI
16	Reddy PH, Tonk S, Kumar S, Vijayan M, Kandimalla R, Kuruva CS and Reddy AP: A critical evaluation of neuropro-tective and neurodegenerative MicroRNAs in Alzheimer's disease. Biochem Biophys Res Commun. 483:1156–1165. 2017. View Article : Google Scholar
17	Nelson PT and Wang WX: MiR-107 is reduced in Alzheimer's disease brain neocortex: Validation study. J Alzheimer's Dis. 21:75–79. 2010. View Article : Google Scholar
18	Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I and Nelson PT: The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 28:1213–1223. 2008. View Article : Google Scholar : PubMed/NCBI
19	Jiao Y, Kong L, Yao Y, Li S, Tao Z, Yan Y and Yang J: Osthole decreases beta amyloid levels through up-regulation of miR-107 in Alzheimer's disease. Neuropharmacology. 108:332–344. 2016. View Article : Google Scholar : PubMed/NCBI
20	Kim TI, Lee YK, Park SG, Choi IS, Ban JO, Park HK, Nam SY, Yun YW, Han SB, Oh KW and Hong JT: l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: Reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. Free Radic Biol Med. 47:1601–1610. 2009. View Article : Google Scholar : PubMed/NCBI
21	Li J, Chen H, Wu S, Cheng Y, Li Q, Wang J and Zhu G: MPP+ inhibits mGluR1/5-mediated long-term depression in mouse hippocampus by calpain activation. Eur J Pharmacol. 795:22–27. 2017. View Article : Google Scholar
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
23	Yang ZB, Zhang Z, Li TB, Lou Z, Li SY, Yang H, Yang J, Luo XJ and Peng J: Up-regulation of brain-enriched miR-107 promotes excitatory neurotoxicity through down-regulation of glutamate transporter-1 expression following ischaemic stroke. Clin Sci (Lond). 127:679–689. 2014. View Article : Google Scholar
24	Wang WX, Wilfred BR, Madathil SK, Tang G, Hu Y, Dimayuga J, Stromberg AJ, Huang Q, Saatman KE and Nelson PT: miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. Am J Pathol. 177:334–345. 2010. View Article : Google Scholar : PubMed/NCBI
25	Chang RK, Li X, Mu N, Hrydziuszko O, Garcia-Majano B, Larsson C and Lui WO: MicroRNA expression profiles in nonepithelial ovarian tumors. Int J Oncol. 52:55–66. 2017.
26	Cao K, Li J, Chen J, Qian L, Wang A, Chen X, Xiong W, Tang J, Tang S, Chen Y, et al: microRNA-33a-5p increases radiosen-sitivity by inhibiting glycolysis in melanoma. Oncotarget. 8:83660–83672. 2017.PubMed/NCBI
27	Müller M, Kuiperij HB, Claassen JA, Küsters B and Verbeek MM: MicroRNAs in Alzheimer's disease: Differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging. 35:152–158. 2014. View Article : Google Scholar
28	Liu W, Cai H, Lin M, Zhu L, Gao L, Zhong R, Bi S, Xue Y and Shang X: MicroRNA-107 prevents amyloid-beta induced blood-brain barrier disruption and endothelial cell dysfunction by targeting Endophilin-1. Exp Cell Res. 343:248–257. 2016. View Article : Google Scholar : PubMed/NCBI
29	Yao J, Hennessey T, Flynt A, Lai E, Beal MF and Lin MT: MicroRNA-related cofilin abnormality in Alzheimer's disease. PLoS One. 5:e155462010. View Article : Google Scholar : PubMed/NCBI
30	Li JJ, Dolios G, Wang R and Liao FF: Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression. PLoS One. 9:e907702014. View Article : Google Scholar : PubMed/NCBI
31	Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M and Dunaevsky A: Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci. 33:274–282. 2006. View Article : Google Scholar : PubMed/NCBI
32	Huang YF, Yang CH, Huang CC and Hsu KS: Vascular endothelial growth factor-dependent spinogenesis underlies antidepressant-like effects of enriched environment. J Biol Chem. 287:40938–40955. 2012. View Article : Google Scholar : PubMed/NCBI
33	Cooke SF and Bliss TV: Long-term potentiation and cognitive drug discovery. Curr Opin Investig Drugs. 6:25–34. 2005.PubMed/NCBI
34	Bliss TV, Collingridge GL and Morris RG: Introduction = Long-term potentiation and structure of the issue. Philos Trans R Soc Lond B, Biol Sci. 358:607–611. 2003. View Article : Google Scholar
35	Zhu G, Liu Y, Wang Y, Bi X and Baudry M: Different patterns of electrical activity lead to long-term potentiation by activating different intracellular pathways. J Neurosci. 35:621–633. 2015. View Article : Google Scholar : PubMed/NCBI
36	Borba EM, Duarte JA, Bristot G, Scotton E, Camozzato AL and Chaves ML: Brain-derived neurotrophic factor serum levels and hippocampal volume in mild cognitive impairment and dementia due to Alzheimer disease. Dement Geriatr Cogn Dis Extra. 6:559–567. 2016. View Article : Google Scholar
37	Nie J, Tian Y, Zhang Y, Lu YL, Li LS and Shi JS: Dendrobium alkaloids prevent Abeta25-35-induced neuronal and synaptic loss via promoting neurotrophic factors expression in mice. PeerJ. 4:e27392016. View Article : Google Scholar
38	Braak H and Braak E: Ratio of pyramidal cells versus non-pyramidal cells in the human frontal isocortex and changes in ratio with ageing and Alzheimer's disease. Prog Brain Res. 70:185–212. 1986. View Article : Google Scholar : PubMed/NCBI
39	Ditter SM and Mirra SS: Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology. 37:754–760. 1987. View Article : Google Scholar : PubMed/NCBI
40	Maingret V, Barthet G, Deforges S, Jiang N, Mulle C and Amédée T: PGE2-EP3 signaling pathway impairs hippocampal presynaptic long-term plasticity in a mouse model of Alzheimer's disease. Neurobiology Aging. 50:13–24. 2017. View Article : Google Scholar
41	Saleem S and Biswas SC: Tribbles Pseudokinase 3 induces both apoptosis and autophagy in amyloid-β-induced neuronal death. J Biol Chem. 292:2571–2585. 2017. View Article : Google Scholar
42	Xiao H, Zhang Q, Peng Y, Tang G, Liao Y, Zhuang X, Ye WC, Wang Y and Shi L: 7-(4-Hydroxy-3-methoxyphenyl)-1-phenyl-4E- hepten-3-one alleviates Abeta1-42 induced cytotoxicity through PI3K-mTOR pathways. Biochem Biophys Res Commun. 484:365–371. 2017. View Article : Google Scholar : PubMed/NCBI
43	Chen L, Ou S, Zhou L, Tang H, Xu J and Guo K: Formononetin attenuates Aβ25-35-induced cytotoxicity in HT22 cells via PI3K/Akt signaling and non-amyloidogenic cleavage of APP. Neurosci Lett. 639:36–42. 2017. View Article : Google Scholar
44	Zhu G, Wang X, Wu S and Li Q: Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+-induced human neuroblastoma SH-SY5Y cell death. Neurochem Int. 60:400–408. 2012. View Article : Google Scholar : PubMed/NCBI
45	Li Y, Mao L, Gao Y, Baral S, Zhou Y and Hu B: MicroRNA-107 contributes to post-stroke angiogenesis by targeting Dicer-1. Sci Rep. 5:133162015. View Article : Google Scholar : PubMed/NCBI
46	Xia H, Li Y and Lv X: MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer. Int J Oncol. 49:1325–1333. 2016. View Article : Google Scholar : PubMed/NCBI
47	Qian Q, Liu Q, Zhou D, Pan H, Liu Z, He F, Ji S, Wang D, Bao W, Liu X, et al: Brain-specific ablation of Efr3a promotes adult hippocampal neurogenesis via the brain-derived neurotrophic factor pathway. FASEB J. 31:2104–2113. 2017. View Article : Google Scholar : PubMed/NCBI